South Africa’s Competition Tribunal has reportedly approved of the Nestle-Pfizer Nutrition baby formula merger, but with hard-hitting conditions, according to reports. Nestle and Pfizer stand as the largest and third-largest infant formula market in the country. The approval’s catch, however, requires a large divestment from Pfizer of its infant milk formula business, as the Tribunal found that the merger would leave only Aspen as a top competitor in the market. The Tribunal has included a list of concessions the parties need to address before the merger goes through. According to reports, remedies that have been suggested are similar to the remedies used to approve of the same deal in Australia; under the terms, Pfizer would reportedly divest its infant milk formula business in South Africa, and its new owner would rebrand the company and its products.
Featured News
Jiangxi Copper Finalizes SolGold Acquisition, Expanding China’s Hold on Ecuadorian Copper Projects
Mar 11, 2026 by
CPI
US Judge Rejects Drugmakers’ Bid to Disqualify Former Prosecutor in Price-Fixing Lawsuits
Mar 11, 2026 by
CPI
Spain Plans New Digital Tool to Measure ‘Footprint of Hate’ Online
Mar 11, 2026 by
CPI
Paul Hastings Hires EU Competition Partner for Brussels Office
Mar 11, 2026 by
CPI
Lawmakers Push for Better Data as AI’s Workforce Impact Comes into Focus
Mar 11, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Behavioral Economics
Feb 22, 2026 by
CPI
Behavioral Antitrust in 2026
Feb 22, 2026 by
Maurice Stucke
Behavioral Economics in Competition Policy: Going Beyond Inertia and Framing Effects
Feb 22, 2026 by
Annemieke Tuinstra & Richard May
Agreeing to Disagree in Antitrust
Feb 22, 2026 by
Jorge Padilla
Recognizing What’s Around the Corner: Merger Control, Capabilities, and the New Nature of Potential Competition
Feb 22, 2026 by
Magdalena Kuyterink & David J. Teece